nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—AHR—liver cancer	0.627	1	CbGaD
Leflunomide—ABCG2—Sorafenib—liver cancer	0.0676	0.418	CbGbCtD
Leflunomide—ABCG2—Doxorubicin—liver cancer	0.041	0.254	CbGbCtD
Leflunomide—CYP1A2—Sorafenib—liver cancer	0.0279	0.172	CbGbCtD
Leflunomide—CYP2C9—Sorafenib—liver cancer	0.0251	0.155	CbGbCtD
Leflunomide—Bladder pain—Doxorubicin—liver cancer	0.000248	0.00216	CcSEcCtD
Leflunomide—Neoplasm—Doxorubicin—liver cancer	0.000248	0.00216	CcSEcCtD
Leflunomide—Ecchymosis—Doxorubicin—liver cancer	0.000248	0.00216	CcSEcCtD
Leflunomide—Mouth ulceration—Doxorubicin—liver cancer	0.000248	0.00216	CcSEcCtD
Leflunomide—Diabetes mellitus—Epirubicin—liver cancer	0.000247	0.00215	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Sorafenib—liver cancer	0.000247	0.00215	CcSEcCtD
Leflunomide—Fatigue—Sorafenib—liver cancer	0.000246	0.00215	CcSEcCtD
Leflunomide—Constipation—Sorafenib—liver cancer	0.000244	0.00213	CcSEcCtD
Leflunomide—Pain—Sorafenib—liver cancer	0.000244	0.00213	CcSEcCtD
Leflunomide—Eczema—Epirubicin—liver cancer	0.000239	0.00209	CcSEcCtD
Leflunomide—Hepatic failure—Epirubicin—liver cancer	0.000239	0.00209	CcSEcCtD
Leflunomide—Sepsis—Doxorubicin—liver cancer	0.000238	0.00207	CcSEcCtD
Leflunomide—Gastrointestinal pain—Sorafenib—liver cancer	0.000234	0.00204	CcSEcCtD
Leflunomide—Lymphadenopathy—Doxorubicin—liver cancer	0.000233	0.00203	CcSEcCtD
Leflunomide—Diabetes mellitus—Doxorubicin—liver cancer	0.000229	0.00199	CcSEcCtD
Leflunomide—Urticaria—Sorafenib—liver cancer	0.000227	0.00198	CcSEcCtD
Leflunomide—Abdominal pain—Sorafenib—liver cancer	0.000226	0.00197	CcSEcCtD
Leflunomide—Body temperature increased—Sorafenib—liver cancer	0.000226	0.00197	CcSEcCtD
Leflunomide—Anaphylactoid reaction—Epirubicin—liver cancer	0.000222	0.00194	CcSEcCtD
Leflunomide—Eczema—Doxorubicin—liver cancer	0.000221	0.00193	CcSEcCtD
Leflunomide—Hepatic failure—Doxorubicin—liver cancer	0.000221	0.00193	CcSEcCtD
Leflunomide—Osteoarthritis—Epirubicin—liver cancer	0.000215	0.00187	CcSEcCtD
Leflunomide—Migraine—Epirubicin—liver cancer	0.000211	0.00184	CcSEcCtD
Leflunomide—Hypersensitivity—Sorafenib—liver cancer	0.000211	0.00184	CcSEcCtD
Leflunomide—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000205	0.00179	CcSEcCtD
Leflunomide—Asthenia—Sorafenib—liver cancer	0.000205	0.00179	CcSEcCtD
Leflunomide—Pruritus—Sorafenib—liver cancer	0.000202	0.00176	CcSEcCtD
Leflunomide—Osteoarthritis—Doxorubicin—liver cancer	0.000199	0.00173	CcSEcCtD
Leflunomide—Liver function test abnormal—Epirubicin—liver cancer	0.000198	0.00173	CcSEcCtD
Leflunomide—Dry skin—Epirubicin—liver cancer	0.000197	0.00172	CcSEcCtD
Leflunomide—Migraine—Doxorubicin—liver cancer	0.000196	0.00171	CcSEcCtD
Leflunomide—Hypokalaemia—Epirubicin—liver cancer	0.000196	0.00171	CcSEcCtD
Leflunomide—Diarrhoea—Sorafenib—liver cancer	0.000196	0.00171	CcSEcCtD
Leflunomide—Breast disorder—Epirubicin—liver cancer	0.000194	0.00169	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000193	0.00169	CcSEcCtD
Leflunomide—Gastritis—Epirubicin—liver cancer	0.00019	0.00166	CcSEcCtD
Leflunomide—Dizziness—Sorafenib—liver cancer	0.000189	0.00165	CcSEcCtD
Leflunomide—Asthma—Epirubicin—liver cancer	0.000186	0.00162	CcSEcCtD
Leflunomide—Influenza—Epirubicin—liver cancer	0.000186	0.00162	CcSEcCtD
Leflunomide—Eosinophilia—Epirubicin—liver cancer	0.000184	0.0016	CcSEcCtD
Leflunomide—Liver function test abnormal—Doxorubicin—liver cancer	0.000184	0.0016	CcSEcCtD
Leflunomide—Dry skin—Doxorubicin—liver cancer	0.000182	0.00159	CcSEcCtD
Leflunomide—Pancreatitis—Epirubicin—liver cancer	0.000182	0.00159	CcSEcCtD
Leflunomide—Vomiting—Sorafenib—liver cancer	0.000182	0.00158	CcSEcCtD
Leflunomide—Hypokalaemia—Doxorubicin—liver cancer	0.000181	0.00158	CcSEcCtD
Leflunomide—Angina pectoris—Epirubicin—liver cancer	0.000181	0.00158	CcSEcCtD
Leflunomide—Rash—Sorafenib—liver cancer	0.00018	0.00157	CcSEcCtD
Leflunomide—Dermatitis—Sorafenib—liver cancer	0.00018	0.00157	CcSEcCtD
Leflunomide—Breast disorder—Doxorubicin—liver cancer	0.00018	0.00157	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000179	0.00156	CcSEcCtD
Leflunomide—Headache—Sorafenib—liver cancer	0.000179	0.00156	CcSEcCtD
Leflunomide—Bronchitis—Epirubicin—liver cancer	0.000179	0.00156	CcSEcCtD
Leflunomide—Pancytopenia—Epirubicin—liver cancer	0.000176	0.00154	CcSEcCtD
Leflunomide—Gastritis—Doxorubicin—liver cancer	0.000176	0.00153	CcSEcCtD
Leflunomide—Neutropenia—Epirubicin—liver cancer	0.000174	0.00151	CcSEcCtD
Leflunomide—Dysuria—Epirubicin—liver cancer	0.000174	0.00151	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Epirubicin—liver cancer	0.000173	0.00151	CcSEcCtD
Leflunomide—Influenza—Doxorubicin—liver cancer	0.000172	0.0015	CcSEcCtD
Leflunomide—Asthma—Doxorubicin—liver cancer	0.000172	0.0015	CcSEcCtD
Leflunomide—Pollakiuria—Epirubicin—liver cancer	0.000172	0.0015	CcSEcCtD
Leflunomide—Eosinophilia—Doxorubicin—liver cancer	0.00017	0.00148	CcSEcCtD
Leflunomide—Nausea—Sorafenib—liver cancer	0.00017	0.00148	CcSEcCtD
Leflunomide—Pancreatitis—Doxorubicin—liver cancer	0.000168	0.00147	CcSEcCtD
Leflunomide—Weight decreased—Epirubicin—liver cancer	0.000168	0.00147	CcSEcCtD
Leflunomide—Hyperglycaemia—Epirubicin—liver cancer	0.000168	0.00146	CcSEcCtD
Leflunomide—Angina pectoris—Doxorubicin—liver cancer	0.000167	0.00146	CcSEcCtD
Leflunomide—Pneumonia—Epirubicin—liver cancer	0.000167	0.00145	CcSEcCtD
Leflunomide—Infestation NOS—Epirubicin—liver cancer	0.000166	0.00144	CcSEcCtD
Leflunomide—Infestation—Epirubicin—liver cancer	0.000166	0.00144	CcSEcCtD
Leflunomide—Bronchitis—Doxorubicin—liver cancer	0.000165	0.00144	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000164	0.00143	CcSEcCtD
Leflunomide—Pancytopenia—Doxorubicin—liver cancer	0.000163	0.00142	CcSEcCtD
Leflunomide—Renal failure—Epirubicin—liver cancer	0.000163	0.00142	CcSEcCtD
Leflunomide—Neuropathy peripheral—Epirubicin—liver cancer	0.000162	0.00142	CcSEcCtD
Leflunomide—Jaundice—Epirubicin—liver cancer	0.000161	0.00141	CcSEcCtD
Leflunomide—Stomatitis—Epirubicin—liver cancer	0.000161	0.00141	CcSEcCtD
Leflunomide—Urinary tract infection—Epirubicin—liver cancer	0.000161	0.0014	CcSEcCtD
Leflunomide—Conjunctivitis—Epirubicin—liver cancer	0.000161	0.0014	CcSEcCtD
Leflunomide—Dysuria—Doxorubicin—liver cancer	0.000161	0.0014	CcSEcCtD
Leflunomide—Neutropenia—Doxorubicin—liver cancer	0.000161	0.0014	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00016	0.00139	CcSEcCtD
Leflunomide—Pollakiuria—Doxorubicin—liver cancer	0.000159	0.00138	CcSEcCtD
Leflunomide—Haematuria—Epirubicin—liver cancer	0.000158	0.00138	CcSEcCtD
Leflunomide—Hepatobiliary disease—Epirubicin—liver cancer	0.000157	0.00137	CcSEcCtD
Leflunomide—Epistaxis—Epirubicin—liver cancer	0.000156	0.00136	CcSEcCtD
Leflunomide—Weight decreased—Doxorubicin—liver cancer	0.000155	0.00136	CcSEcCtD
Leflunomide—Sinusitis—Epirubicin—liver cancer	0.000155	0.00135	CcSEcCtD
Leflunomide—Hyperglycaemia—Doxorubicin—liver cancer	0.000155	0.00135	CcSEcCtD
Leflunomide—Agranulocytosis—Epirubicin—liver cancer	0.000155	0.00135	CcSEcCtD
Leflunomide—Pneumonia—Doxorubicin—liver cancer	0.000154	0.00134	CcSEcCtD
Leflunomide—Infestation NOS—Doxorubicin—liver cancer	0.000153	0.00134	CcSEcCtD
Leflunomide—Infestation—Doxorubicin—liver cancer	0.000153	0.00134	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000152	0.00132	CcSEcCtD
Leflunomide—Renal failure—Doxorubicin—liver cancer	0.000151	0.00131	CcSEcCtD
Leflunomide—Neuropathy peripheral—Doxorubicin—liver cancer	0.00015	0.00131	CcSEcCtD
Leflunomide—Haemoglobin—Epirubicin—liver cancer	0.000149	0.0013	CcSEcCtD
Leflunomide—Jaundice—Doxorubicin—liver cancer	0.000149	0.0013	CcSEcCtD
Leflunomide—Stomatitis—Doxorubicin—liver cancer	0.000149	0.0013	CcSEcCtD
Leflunomide—Rhinitis—Epirubicin—liver cancer	0.000149	0.0013	CcSEcCtD
Leflunomide—Urinary tract infection—Doxorubicin—liver cancer	0.000149	0.0013	CcSEcCtD
Leflunomide—Conjunctivitis—Doxorubicin—liver cancer	0.000149	0.0013	CcSEcCtD
Leflunomide—Hepatitis—Epirubicin—liver cancer	0.000149	0.0013	CcSEcCtD
Leflunomide—Haemorrhage—Epirubicin—liver cancer	0.000149	0.0013	CcSEcCtD
Leflunomide—Pharyngitis—Epirubicin—liver cancer	0.000148	0.00129	CcSEcCtD
Leflunomide—Urinary tract disorder—Epirubicin—liver cancer	0.000147	0.00128	CcSEcCtD
Leflunomide—Oedema peripheral—Epirubicin—liver cancer	0.000146	0.00128	CcSEcCtD
Leflunomide—Haematuria—Doxorubicin—liver cancer	0.000146	0.00127	CcSEcCtD
Leflunomide—Connective tissue disorder—Epirubicin—liver cancer	0.000146	0.00127	CcSEcCtD
Leflunomide—Urethral disorder—Epirubicin—liver cancer	0.000146	0.00127	CcSEcCtD
Leflunomide—Hepatobiliary disease—Doxorubicin—liver cancer	0.000145	0.00126	CcSEcCtD
Leflunomide—Epistaxis—Doxorubicin—liver cancer	0.000145	0.00126	CcSEcCtD
Leflunomide—Sinusitis—Doxorubicin—liver cancer	0.000144	0.00125	CcSEcCtD
Leflunomide—Agranulocytosis—Doxorubicin—liver cancer	0.000143	0.00125	CcSEcCtD
Leflunomide—Erythema multiforme—Epirubicin—liver cancer	0.000141	0.00123	CcSEcCtD
Leflunomide—Eye disorder—Epirubicin—liver cancer	0.000139	0.00121	CcSEcCtD
Leflunomide—Haemoglobin—Doxorubicin—liver cancer	0.000138	0.00121	CcSEcCtD
Leflunomide—Cardiac disorder—Epirubicin—liver cancer	0.000138	0.0012	CcSEcCtD
Leflunomide—Rhinitis—Doxorubicin—liver cancer	0.000138	0.0012	CcSEcCtD
Leflunomide—Hepatitis—Doxorubicin—liver cancer	0.000138	0.0012	CcSEcCtD
Leflunomide—Haemorrhage—Doxorubicin—liver cancer	0.000138	0.0012	CcSEcCtD
Leflunomide—Pharyngitis—Doxorubicin—liver cancer	0.000137	0.00119	CcSEcCtD
Leflunomide—Urinary tract disorder—Doxorubicin—liver cancer	0.000136	0.00118	CcSEcCtD
Leflunomide—Oedema peripheral—Doxorubicin—liver cancer	0.000135	0.00118	CcSEcCtD
Leflunomide—Connective tissue disorder—Doxorubicin—liver cancer	0.000135	0.00118	CcSEcCtD
Leflunomide—Urethral disorder—Doxorubicin—liver cancer	0.000135	0.00118	CcSEcCtD
Leflunomide—Immune system disorder—Epirubicin—liver cancer	0.000134	0.00117	CcSEcCtD
Leflunomide—Mediastinal disorder—Epirubicin—liver cancer	0.000134	0.00117	CcSEcCtD
Leflunomide—Chills—Epirubicin—liver cancer	0.000133	0.00116	CcSEcCtD
Leflunomide—Arrhythmia—Epirubicin—liver cancer	0.000133	0.00116	CcSEcCtD
Leflunomide—Alopecia—Epirubicin—liver cancer	0.000131	0.00115	CcSEcCtD
Leflunomide—Mental disorder—Epirubicin—liver cancer	0.00013	0.00114	CcSEcCtD
Leflunomide—Erythema multiforme—Doxorubicin—liver cancer	0.00013	0.00113	CcSEcCtD
Leflunomide—Malnutrition—Epirubicin—liver cancer	0.000129	0.00113	CcSEcCtD
Leflunomide—Eye disorder—Doxorubicin—liver cancer	0.000129	0.00112	CcSEcCtD
Leflunomide—Cardiac disorder—Doxorubicin—liver cancer	0.000128	0.00111	CcSEcCtD
Leflunomide—Flatulence—Epirubicin—liver cancer	0.000128	0.00111	CcSEcCtD
Leflunomide—Dysgeusia—Epirubicin—liver cancer	0.000127	0.00111	CcSEcCtD
Leflunomide—Back pain—Epirubicin—liver cancer	0.000125	0.00109	CcSEcCtD
Leflunomide—Muscle spasms—Epirubicin—liver cancer	0.000124	0.00108	CcSEcCtD
Leflunomide—Immune system disorder—Doxorubicin—liver cancer	0.000124	0.00108	CcSEcCtD
Leflunomide—Mediastinal disorder—Doxorubicin—liver cancer	0.000124	0.00108	CcSEcCtD
Leflunomide—Chills—Doxorubicin—liver cancer	0.000123	0.00108	CcSEcCtD
Leflunomide—Arrhythmia—Doxorubicin—liver cancer	0.000123	0.00107	CcSEcCtD
Leflunomide—Vision blurred—Epirubicin—liver cancer	0.000122	0.00106	CcSEcCtD
Leflunomide—Alopecia—Doxorubicin—liver cancer	0.000122	0.00106	CcSEcCtD
Leflunomide—Mental disorder—Doxorubicin—liver cancer	0.00012	0.00105	CcSEcCtD
Leflunomide—Ill-defined disorder—Epirubicin—liver cancer	0.00012	0.00105	CcSEcCtD
Leflunomide—Malnutrition—Doxorubicin—liver cancer	0.00012	0.00104	CcSEcCtD
Leflunomide—Anaemia—Epirubicin—liver cancer	0.00012	0.00104	CcSEcCtD
Leflunomide—Flatulence—Doxorubicin—liver cancer	0.000118	0.00103	CcSEcCtD
Leflunomide—Dysgeusia—Doxorubicin—liver cancer	0.000117	0.00102	CcSEcCtD
Leflunomide—Malaise—Epirubicin—liver cancer	0.000117	0.00102	CcSEcCtD
Leflunomide—Vertigo—Epirubicin—liver cancer	0.000116	0.00101	CcSEcCtD
Leflunomide—Leukopenia—Epirubicin—liver cancer	0.000116	0.00101	CcSEcCtD
Leflunomide—Back pain—Doxorubicin—liver cancer	0.000116	0.00101	CcSEcCtD
Leflunomide—Muscle spasms—Doxorubicin—liver cancer	0.000115	0.001	CcSEcCtD
Leflunomide—Palpitations—Epirubicin—liver cancer	0.000114	0.000997	CcSEcCtD
Leflunomide—Cough—Epirubicin—liver cancer	0.000113	0.000985	CcSEcCtD
Leflunomide—Vision blurred—Doxorubicin—liver cancer	0.000113	0.000984	CcSEcCtD
Leflunomide—Hypertension—Epirubicin—liver cancer	0.000112	0.000974	CcSEcCtD
Leflunomide—Ill-defined disorder—Doxorubicin—liver cancer	0.000111	0.000969	CcSEcCtD
Leflunomide—Anaemia—Doxorubicin—liver cancer	0.000111	0.000965	CcSEcCtD
Leflunomide—Arthralgia—Epirubicin—liver cancer	0.00011	0.000961	CcSEcCtD
Leflunomide—Chest pain—Epirubicin—liver cancer	0.00011	0.000961	CcSEcCtD
Leflunomide—Myalgia—Epirubicin—liver cancer	0.00011	0.000961	CcSEcCtD
Leflunomide—Anxiety—Epirubicin—liver cancer	0.00011	0.000957	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000109	0.000954	CcSEcCtD
Leflunomide—Discomfort—Epirubicin—liver cancer	0.000109	0.000949	CcSEcCtD
Leflunomide—Malaise—Doxorubicin—liver cancer	0.000108	0.000942	CcSEcCtD
Leflunomide—Dry mouth—Epirubicin—liver cancer	0.000108	0.00094	CcSEcCtD
Leflunomide—Vertigo—Doxorubicin—liver cancer	0.000108	0.000938	CcSEcCtD
Leflunomide—Leukopenia—Doxorubicin—liver cancer	0.000107	0.000935	CcSEcCtD
Leflunomide—Palpitations—Doxorubicin—liver cancer	0.000106	0.000923	CcSEcCtD
Leflunomide—Anaphylactic shock—Epirubicin—liver cancer	0.000106	0.000921	CcSEcCtD
Leflunomide—Infection—Epirubicin—liver cancer	0.000105	0.000915	CcSEcCtD
Leflunomide—Cough—Doxorubicin—liver cancer	0.000104	0.000911	CcSEcCtD
Leflunomide—Nervous system disorder—Epirubicin—liver cancer	0.000104	0.000903	CcSEcCtD
Leflunomide—Thrombocytopenia—Epirubicin—liver cancer	0.000103	0.000902	CcSEcCtD
Leflunomide—Hypertension—Doxorubicin—liver cancer	0.000103	0.000902	CcSEcCtD
Leflunomide—Tachycardia—Epirubicin—liver cancer	0.000103	0.000899	CcSEcCtD
Leflunomide—Skin disorder—Epirubicin—liver cancer	0.000103	0.000895	CcSEcCtD
Leflunomide—Hyperhidrosis—Epirubicin—liver cancer	0.000102	0.00089	CcSEcCtD
Leflunomide—Myalgia—Doxorubicin—liver cancer	0.000102	0.000889	CcSEcCtD
Leflunomide—Chest pain—Doxorubicin—liver cancer	0.000102	0.000889	CcSEcCtD
Leflunomide—Arthralgia—Doxorubicin—liver cancer	0.000102	0.000889	CcSEcCtD
Leflunomide—Anxiety—Doxorubicin—liver cancer	0.000102	0.000886	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000101	0.000883	CcSEcCtD
Leflunomide—Discomfort—Doxorubicin—liver cancer	0.000101	0.000878	CcSEcCtD
Leflunomide—Anorexia—Epirubicin—liver cancer	0.000101	0.000878	CcSEcCtD
Leflunomide—Dry mouth—Doxorubicin—liver cancer	9.97e-05	0.000869	CcSEcCtD
Leflunomide—Hypotension—Epirubicin—liver cancer	9.87e-05	0.000861	CcSEcCtD
Leflunomide—Anaphylactic shock—Doxorubicin—liver cancer	9.77e-05	0.000852	CcSEcCtD
Leflunomide—Infection—Doxorubicin—liver cancer	9.71e-05	0.000847	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Epirubicin—liver cancer	9.62e-05	0.000839	CcSEcCtD
Leflunomide—Nervous system disorder—Doxorubicin—liver cancer	9.58e-05	0.000836	CcSEcCtD
Leflunomide—Thrombocytopenia—Doxorubicin—liver cancer	9.57e-05	0.000834	CcSEcCtD
Leflunomide—Insomnia—Epirubicin—liver cancer	9.55e-05	0.000833	CcSEcCtD
Leflunomide—Tachycardia—Doxorubicin—liver cancer	9.54e-05	0.000832	CcSEcCtD
Leflunomide—Skin disorder—Doxorubicin—liver cancer	9.49e-05	0.000828	CcSEcCtD
Leflunomide—Paraesthesia—Epirubicin—liver cancer	9.48e-05	0.000827	CcSEcCtD
Leflunomide—Hyperhidrosis—Doxorubicin—liver cancer	9.45e-05	0.000824	CcSEcCtD
Leflunomide—Dyspnoea—Epirubicin—liver cancer	9.42e-05	0.000821	CcSEcCtD
Leflunomide—Anorexia—Doxorubicin—liver cancer	9.31e-05	0.000812	CcSEcCtD
Leflunomide—Dyspepsia—Epirubicin—liver cancer	9.3e-05	0.000811	CcSEcCtD
Leflunomide—Decreased appetite—Epirubicin—liver cancer	9.18e-05	0.000801	CcSEcCtD
Leflunomide—Hypotension—Doxorubicin—liver cancer	9.13e-05	0.000796	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Epirubicin—liver cancer	9.12e-05	0.000795	CcSEcCtD
Leflunomide—Fatigue—Epirubicin—liver cancer	9.11e-05	0.000794	CcSEcCtD
Leflunomide—Pain—Epirubicin—liver cancer	9.03e-05	0.000788	CcSEcCtD
Leflunomide—Constipation—Epirubicin—liver cancer	9.03e-05	0.000788	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Doxorubicin—liver cancer	8.9e-05	0.000776	CcSEcCtD
Leflunomide—Insomnia—Doxorubicin—liver cancer	8.84e-05	0.000771	CcSEcCtD
Leflunomide—Paraesthesia—Doxorubicin—liver cancer	8.77e-05	0.000765	CcSEcCtD
Leflunomide—Dyspnoea—Doxorubicin—liver cancer	8.71e-05	0.00076	CcSEcCtD
Leflunomide—Feeling abnormal—Epirubicin—liver cancer	8.7e-05	0.000759	CcSEcCtD
Leflunomide—Gastrointestinal pain—Epirubicin—liver cancer	8.64e-05	0.000753	CcSEcCtD
Leflunomide—Dyspepsia—Doxorubicin—liver cancer	8.6e-05	0.00075	CcSEcCtD
Leflunomide—Decreased appetite—Doxorubicin—liver cancer	8.49e-05	0.000741	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Doxorubicin—liver cancer	8.44e-05	0.000736	CcSEcCtD
Leflunomide—Fatigue—Doxorubicin—liver cancer	8.42e-05	0.000735	CcSEcCtD
Leflunomide—Urticaria—Epirubicin—liver cancer	8.39e-05	0.000732	CcSEcCtD
Leflunomide—Pain—Doxorubicin—liver cancer	8.36e-05	0.000729	CcSEcCtD
Leflunomide—Constipation—Doxorubicin—liver cancer	8.36e-05	0.000729	CcSEcCtD
Leflunomide—Body temperature increased—Epirubicin—liver cancer	8.35e-05	0.000728	CcSEcCtD
Leflunomide—Abdominal pain—Epirubicin—liver cancer	8.35e-05	0.000728	CcSEcCtD
Leflunomide—Feeling abnormal—Doxorubicin—liver cancer	8.05e-05	0.000702	CcSEcCtD
Leflunomide—Gastrointestinal pain—Doxorubicin—liver cancer	7.99e-05	0.000697	CcSEcCtD
Leflunomide—Hypersensitivity—Epirubicin—liver cancer	7.78e-05	0.000679	CcSEcCtD
Leflunomide—Urticaria—Doxorubicin—liver cancer	7.76e-05	0.000677	CcSEcCtD
Leflunomide—Abdominal pain—Doxorubicin—liver cancer	7.72e-05	0.000674	CcSEcCtD
Leflunomide—Body temperature increased—Doxorubicin—liver cancer	7.72e-05	0.000674	CcSEcCtD
Leflunomide—Asthenia—Epirubicin—liver cancer	7.58e-05	0.000661	CcSEcCtD
Leflunomide—Pruritus—Epirubicin—liver cancer	7.47e-05	0.000652	CcSEcCtD
Leflunomide—Diarrhoea—Epirubicin—liver cancer	7.23e-05	0.00063	CcSEcCtD
Leflunomide—Hypersensitivity—Doxorubicin—liver cancer	7.2e-05	0.000628	CcSEcCtD
Leflunomide—Asthenia—Doxorubicin—liver cancer	7.01e-05	0.000611	CcSEcCtD
Leflunomide—Dizziness—Epirubicin—liver cancer	6.98e-05	0.000609	CcSEcCtD
Leflunomide—Pruritus—Doxorubicin—liver cancer	6.91e-05	0.000603	CcSEcCtD
Leflunomide—Vomiting—Epirubicin—liver cancer	6.71e-05	0.000586	CcSEcCtD
Leflunomide—Diarrhoea—Doxorubicin—liver cancer	6.69e-05	0.000583	CcSEcCtD
Leflunomide—Rash—Epirubicin—liver cancer	6.66e-05	0.000581	CcSEcCtD
Leflunomide—Dermatitis—Epirubicin—liver cancer	6.65e-05	0.00058	CcSEcCtD
Leflunomide—Headache—Epirubicin—liver cancer	6.62e-05	0.000577	CcSEcCtD
Leflunomide—Dizziness—Doxorubicin—liver cancer	6.46e-05	0.000564	CcSEcCtD
Leflunomide—Nausea—Epirubicin—liver cancer	6.27e-05	0.000547	CcSEcCtD
Leflunomide—Vomiting—Doxorubicin—liver cancer	6.21e-05	0.000542	CcSEcCtD
Leflunomide—Rash—Doxorubicin—liver cancer	6.16e-05	0.000537	CcSEcCtD
Leflunomide—Dermatitis—Doxorubicin—liver cancer	6.16e-05	0.000537	CcSEcCtD
Leflunomide—Headache—Doxorubicin—liver cancer	6.12e-05	0.000534	CcSEcCtD
Leflunomide—Nausea—Doxorubicin—liver cancer	5.8e-05	0.000506	CcSEcCtD
Leflunomide—PTK2B—Immune System—ADAM17—liver cancer	5.33e-05	0.000551	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—HRAS—liver cancer	5.29e-05	0.000547	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—liver cancer	5.28e-05	0.000546	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—UGDH—liver cancer	5.18e-05	0.000536	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—AKT1—liver cancer	5.13e-05	0.000531	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—HPGDS—liver cancer	5.1e-05	0.000528	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PIK3CD—liver cancer	5.04e-05	0.000521	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PSMA4—liver cancer	5.02e-05	0.000518	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PSMD10—liver cancer	5.02e-05	0.000518	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—ALB—liver cancer	4.98e-05	0.000515	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—EPT1—liver cancer	4.87e-05	0.000504	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—CYP2E1—liver cancer	4.87e-05	0.000503	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—liver cancer	4.84e-05	0.0005	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—liver cancer	4.84e-05	0.0005	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP2E1—liver cancer	4.8e-05	0.000496	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FST—liver cancer	4.77e-05	0.000493	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—liver cancer	4.73e-05	0.000489	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—EPT1—liver cancer	4.72e-05	0.000488	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—STAT3—liver cancer	4.68e-05	0.000484	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—AKT1—liver cancer	4.67e-05	0.000483	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—TAT—liver cancer	4.62e-05	0.000477	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—liver cancer	4.6e-05	0.000476	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TRIO—liver cancer	4.55e-05	0.00047	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—GGT1—liver cancer	4.47e-05	0.000462	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—liver cancer	4.46e-05	0.000461	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—AKT1—liver cancer	4.46e-05	0.000461	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PIK3CB—liver cancer	4.4e-05	0.000454	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IFNA1—liver cancer	4.39e-05	0.000454	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCR4—liver cancer	4.36e-05	0.000451	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—CYP2E1—liver cancer	4.16e-05	0.00043	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP2E1—liver cancer	4.1e-05	0.000424	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—liver cancer	4.02e-05	0.000416	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—KRAS—liver cancer	4.02e-05	0.000415	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—GSTP1—liver cancer	4.02e-05	0.000415	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—GSTP1—liver cancer	3.96e-05	0.000409	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PRKCE—liver cancer	3.89e-05	0.000402	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—GGT1—liver cancer	3.82e-05	0.000395	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—liver cancer	3.7e-05	0.000383	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ABL1—liver cancer	3.7e-05	0.000382	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—liver cancer	3.69e-05	0.000382	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PIK3CA—liver cancer	3.69e-05	0.000382	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—GSTM1—liver cancer	3.69e-05	0.000382	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—GSTM1—liver cancer	3.64e-05	0.000376	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	3.56e-05	0.000368	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—CYP1A1—liver cancer	3.5e-05	0.000362	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HGF—liver cancer	3.48e-05	0.000359	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP1A1—liver cancer	3.45e-05	0.000357	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ADAM17—liver cancer	3.45e-05	0.000357	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—liver cancer	3.45e-05	0.000356	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—liver cancer	3.45e-05	0.000356	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD8A—liver cancer	3.44e-05	0.000355	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CSF2—liver cancer	3.44e-05	0.000355	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	3.43e-05	0.000355	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—GSTP1—liver cancer	3.43e-05	0.000355	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—liver cancer	3.42e-05	0.000354	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HRAS—liver cancer	3.42e-05	0.000353	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—GSTP1—liver cancer	3.38e-05	0.00035	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—CYCS—liver cancer	3.29e-05	0.00034	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL6—liver cancer	3.27e-05	0.000338	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PSMD10—liver cancer	3.24e-05	0.000335	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PSMA4—liver cancer	3.24e-05	0.000335	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—GSTM1—liver cancer	3.15e-05	0.000326	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CPT1B—liver cancer	3.14e-05	0.000324	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GLUL—liver cancer	3.14e-05	0.000324	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—GSTM1—liver cancer	3.11e-05	0.000322	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	3.04e-05	0.000314	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—NR1H4—liver cancer	3.03e-05	0.000313	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—CYP1A1—liver cancer	2.99e-05	0.000309	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTA3—liver cancer	2.98e-05	0.000308	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP1A1—liver cancer	2.95e-05	0.000305	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—BCL2L1—liver cancer	2.94e-05	0.000304	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	2.93e-05	0.000303	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—liver cancer	2.91e-05	0.0003	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—HMOX1—liver cancer	2.86e-05	0.000296	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MAPK14—liver cancer	2.78e-05	0.000288	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTA4—liver cancer	2.72e-05	0.000281	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PIK3CA—liver cancer	2.68e-05	0.000277	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTA2—liver cancer	2.65e-05	0.000274	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	2.62e-05	0.000271	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—UGDH—liver cancer	2.62e-05	0.000271	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTA1—liver cancer	2.56e-05	0.000265	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—NAT2—liver cancer	2.53e-05	0.000262	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PRKCE—liver cancer	2.51e-05	0.00026	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—EPT1—liver cancer	2.46e-05	0.000254	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALDOB—liver cancer	2.43e-05	0.000251	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IGF2—liver cancer	2.38e-05	0.000246	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDH1—liver cancer	2.38e-05	0.000246	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—TAT—liver cancer	2.33e-05	0.000241	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CRABP1—liver cancer	2.31e-05	0.000239	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—PPARA—liver cancer	2.31e-05	0.000239	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	2.29e-05	0.000237	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CD—liver cancer	2.27e-05	0.000235	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	2.24e-05	0.000232	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—UGDH—liver cancer	2.24e-05	0.000231	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CSF2—liver cancer	2.22e-05	0.00023	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—H2AFX—liver cancer	2.19e-05	0.000226	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—AKT1—liver cancer	2.19e-05	0.000226	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—EPT1—liver cancer	2.1e-05	0.000217	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—RAF1—liver cancer	2.03e-05	0.000209	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—HPGDS—liver cancer	2.02e-05	0.000209	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—TAT—liver cancer	1.99e-05	0.000206	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TERT—liver cancer	1.98e-05	0.000205	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CB—liver cancer	1.98e-05	0.000204	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MTOR—liver cancer	1.98e-05	0.000204	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	1.96e-05	0.000203	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDKN1B—liver cancer	1.86e-05	0.000192	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL2—liver cancer	1.82e-05	0.000188	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KDR—liver cancer	1.81e-05	0.000187	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PSMD10—liver cancer	1.8e-05	0.000186	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PSMA4—liver cancer	1.8e-05	0.000186	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAPK14—liver cancer	1.8e-05	0.000186	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—JUN—liver cancer	1.77e-05	0.000183	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ESR1—liver cancer	1.77e-05	0.000183	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GOT2—liver cancer	1.75e-05	0.000181	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CTNNB1—liver cancer	1.75e-05	0.000181	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—F2—liver cancer	1.74e-05	0.00018	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ALB—liver cancer	1.72e-05	0.000178	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	1.72e-05	0.000177	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDKN1A—liver cancer	1.71e-05	0.000177	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MAPK8—liver cancer	1.67e-05	0.000173	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CG—liver cancer	1.67e-05	0.000173	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—APC—liver cancer	1.67e-05	0.000173	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP2E1—liver cancer	1.65e-05	0.00017	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GLUL—liver cancer	1.59e-05	0.000164	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CPT1B—liver cancer	1.59e-05	0.000164	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—BRAF—liver cancer	1.57e-05	0.000162	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—RAF1—liver cancer	1.55e-05	0.000161	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYCS—liver cancer	1.54e-05	0.000159	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NR1H4—liver cancer	1.53e-05	0.000158	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—STAT3—liver cancer	1.53e-05	0.000158	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GGT1—liver cancer	1.51e-05	0.000156	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GOT1—liver cancer	1.51e-05	0.000156	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTA3—liver cancer	1.5e-05	0.000155	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	1.47e-05	0.000152	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CD—liver cancer	1.47e-05	0.000152	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SERPINE1—liver cancer	1.45e-05	0.00015	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTA4—liver cancer	1.37e-05	0.000142	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTP1—liver cancer	1.36e-05	0.000141	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GLUL—liver cancer	1.35e-05	0.00014	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CPT1B—liver cancer	1.35e-05	0.00014	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	1.34e-05	0.000139	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—HMOX1—liver cancer	1.34e-05	0.000139	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTA2—liver cancer	1.34e-05	0.000138	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—KRAS—liver cancer	1.31e-05	0.000136	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RAF1—liver cancer	1.31e-05	0.000135	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NR1H4—liver cancer	1.31e-05	0.000135	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTA1—liver cancer	1.29e-05	0.000134	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTA3—liver cancer	1.28e-05	0.000133	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CB—liver cancer	1.28e-05	0.000132	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MTOR—liver cancer	1.28e-05	0.000132	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NAT2—liver cancer	1.28e-05	0.000132	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTM1—liver cancer	1.25e-05	0.000129	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.23e-05	0.000127	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALDOB—liver cancer	1.23e-05	0.000127	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CA—liver cancer	1.21e-05	0.000125	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN1B—liver cancer	1.2e-05	0.000124	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP1A1—liver cancer	1.18e-05	0.000122	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CASP3—liver cancer	1.18e-05	0.000122	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTA4—liver cancer	1.17e-05	0.000121	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL2—liver cancer	1.17e-05	0.000121	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CRABP1—liver cancer	1.17e-05	0.000121	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	1.15e-05	0.000119	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCND1—liver cancer	1.14e-05	0.000118	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTA2—liver cancer	1.14e-05	0.000118	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—JUN—liver cancer	1.14e-05	0.000118	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CTNNB1—liver cancer	1.13e-05	0.000117	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HRAS—liver cancer	1.12e-05	0.000115	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MMP9—liver cancer	1.11e-05	0.000115	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN1A—liver cancer	1.11e-05	0.000114	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTA1—liver cancer	1.1e-05	0.000114	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—MTHFR—liver cancer	1.1e-05	0.000114	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NAT2—liver cancer	1.09e-05	0.000113	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPARA—liver cancer	1.08e-05	0.000112	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAPK8—liver cancer	1.08e-05	0.000112	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL6—liver cancer	1.07e-05	0.00011	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.05e-05	0.000109	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.05e-05	0.000109	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALDOB—liver cancer	1.05e-05	0.000108	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HPGDS—liver cancer	1.02e-05	0.000106	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.02e-05	0.000105	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CRABP1—liver cancer	9.99e-06	0.000103	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—VEGFA—liver cancer	9.98e-06	0.000103	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—STAT3—liver cancer	9.88e-06	0.000102	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—AKT1—liver cancer	9.85e-06	0.000102	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CG—liver cancer	9.28e-06	9.59e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	9.25e-06	9.56e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MYC—liver cancer	9.18e-06	9.49e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TGFB1—liver cancer	9.16e-06	9.47e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	9.13e-06	9.44e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PSMA4—liver cancer	9.11e-06	9.41e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PSMD10—liver cancer	9.11e-06	9.41e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	8.99e-06	9.3e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPARG—liver cancer	8.96e-06	9.26e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GOT2—liver cancer	8.86e-06	9.16e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HPGDS—liver cancer	8.73e-06	9.02e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	8.68e-06	8.97e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KRAS—liver cancer	8.49e-06	8.77e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP2E1—liver cancer	8.33e-06	8.61e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CD—liver cancer	8.16e-06	8.43e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	8.06e-06	8.34e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALB—liver cancer	8.05e-06	8.32e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	7.91e-06	8.17e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	7.8e-06	8.07e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CA—liver cancer	7.8e-06	8.06e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYCS—liver cancer	7.79e-06	8.05e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PSMA4—liver cancer	7.78e-06	8.04e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PSMD10—liver cancer	7.78e-06	8.04e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GOT1—liver cancer	7.65e-06	7.9e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GGT1—liver cancer	7.65e-06	7.9e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GOT2—liver cancer	7.57e-06	7.82e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—liver cancer	7.54e-06	7.8e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HRAS—liver cancer	7.21e-06	7.46e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP2E1—liver cancer	7.12e-06	7.36e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CB—liver cancer	7.11e-06	7.35e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL6—liver cancer	6.9e-06	7.14e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	6.89e-06	7.12e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTP1—liver cancer	6.87e-06	7.1e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HMOX1—liver cancer	6.77e-06	7e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYCS—liver cancer	6.66e-06	6.88e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GGT1—liver cancer	6.53e-06	6.75e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GOT1—liver cancer	6.53e-06	6.75e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKT1—liver cancer	6.37e-06	6.58e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTM1—liver cancer	6.31e-06	6.52e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP1A1—liver cancer	5.98e-06	6.19e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTP1—liver cancer	5.87e-06	6.07e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HMOX1—liver cancer	5.79e-06	5.98e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—MTHFR—liver cancer	5.58e-06	5.77e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPARA—liver cancer	5.47e-06	5.66e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTM1—liver cancer	5.39e-06	5.58e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP1A1—liver cancer	5.11e-06	5.29e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.92e-06	5.08e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—MTHFR—liver cancer	4.77e-06	4.93e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CG—liver cancer	4.69e-06	4.84e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPARA—liver cancer	4.68e-06	4.83e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPARG—liver cancer	4.52e-06	4.68e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CA—liver cancer	4.33e-06	4.48e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.2e-06	4.34e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CD—liver cancer	4.12e-06	4.26e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALB—liver cancer	4.07e-06	4.2e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CG—liver cancer	4e-06	4.14e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPARG—liver cancer	3.87e-06	4e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CB—liver cancer	3.59e-06	3.71e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKT1—liver cancer	3.54e-06	3.66e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CD—liver cancer	3.52e-06	3.64e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALB—liver cancer	3.48e-06	3.59e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CB—liver cancer	3.07e-06	3.17e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CA—liver cancer	2.19e-06	2.26e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CA—liver cancer	1.87e-06	1.93e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKT1—liver cancer	1.79e-06	1.85e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKT1—liver cancer	1.53e-06	1.58e-05	CbGpPWpGaD
